Stemcell First revolutionises cancer care and prevention

Stemcell First is setting a new benchmark in cancer care and regenerative medicine across Southeast Asia.

With its innovative therapies, advanced diagnostics, and patient-first ethos, the group is transforming healthcare access and outcomes.

“Early detection saves lives,” says Allen Law, COO of Stemcell First.

The group’s cutting-edge Multiple Cancer Early Detection (MCED) screening enables detection of cancers at stage 0, potentially years before symptoms arise.

Founded in 2016 by Richard Lim, Stemcell First is deeply personal. Inspired by Lim’s journey navigating cancer care for his son, the group prioritises trust, compassion, and innovation.

“Our mission is to support families during their toughest times,” says Lim.

Bringing advanced cancer solutions

Stemcell First’s flagship Vanfo Hino Ambulatory Care Centre in Johor Bahru leads its network of clinics.

Specialising in advanced cell and gene therapies, the centre targets cancers such as leukaemia, lymphoma, and ovarian cancer with groundbreaking treatments like CAR-T cell therapy.

Complementing this are the Masayo Clinics in Kuala Lumpur and Johor Bahru, and the SCF Clinic in Bangkok, which focus on regenerative medicine and wellness.

A key offering across all clinics is the MCED screening, capable of identifying anomalies for breast, lung, colorectal, and other cancers early.

This proactive approach reduces treatment costs and improves survival rates, addressing a critical healthcare gap in the region.

“Our goal is to make advanced treatments accessible and affordable,” Law emphasises. “Patients shouldn’t have to travel abroad for world-class care.”

Innovating for a healthier future

Stemcell First’s success is built on innovation and trust. The company adheres to the highest standards, with therapies produced in current Good Manufacturing Practice (cGMP) laboratories.

Beyond cancer, the group offers gene therapies for conditions like spinal muscular atrophy and beta-thalassemia, demonstrating its commitment to diverse healthcare needs.

The upcoming laboratory at Vanfo Hino aims to enhance research capabilities, positioning the group as a leader in Southeast Asia.

Future expansions include entering the Indonesian market, furthering their mission to bring life-changing treatments closer to home.

Stemcell First continues to redefine healthcare with its patient-centred approach.

“At Stemcell First, we put patients first,” says Lim. “Our journey is just beginning, and we’re dedicated to bringing hope, healing, and innovative solutions to communities across the region.”

Visit Stemcell First to learn more about its groundbreaking work and commitment to improving lives.